This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Rare Disease Innovation & Partnership Summit
March 21-23, 2023
Delivered as a Hybrid EventPhiladelphia Marriott Downtown

Elsa Lavita
Director, Patient Advocacy at MorphoSys


Elsa LaVita has grown her patient advocacy career rooted in rare disease and oncology. Elsa is the Director of Patient Advocacy at MorphoSys where she is responsible for ensuring the patient perspective is integrated into the development and commercialization of the company’s cancer medicines. She acts as the bridge between the company and patient communities. Previously, Elsa was the head of patient advocacy at bluebird bio where she partnered with advocacy organizations to ensure the unmet needs and burden of disease faced by rare disease patients was well incorporated in an ICER review and two FDA Advisory Committee meetings, both resulting in unanimous support for novel gene therapies. Elsa holds an MBA from Boston University and a BS from Cornell University.

Agenda Sessions

  • Strengthening Relationships—Putting the Patient in the Driver’s Seat